Datavant Research Portfolio

Datavant supports transparent research that utilizes real-world data in a privacy preserving manner. Below, we highlight research efforts that have used Datavant technology to link real-world data for the benefit of patients and the public good.

All Tags

Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE

Faraz S. Ahmad, Iben M. Ricket, Bradley G. Hammill, Lisa Eskenazi, Holly R. Robertson, Lesley H. Curtis, Cecilia D. Dobi, Saket Girotra, Kevin Haynes, Jorge R. Kizer, Sunil Kripalani, Mathew T. Roe, Christianne L. Roumie, Russ Waitman, W. Schuyler Jones, and Mark G. Weiner

This study outlines the recruitment process for the ADAPTABLE study (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness), a pragmatic, randomized, open-label clinical trial that tested the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events. Investigators identified 650,000 potential eligible patients and recruited them at community sites, linking together data from the 40 sites in the Patient-Centered Outcomes Research Network to understand eligibility. The study was ultimately able to successfully enroll 15,076 patients in a significantly lower-cost way than most trials.

Daily Deaths During Coronavirus Pandemic by State

John Hargraves and Daniel Kurowski

Using mortality data, the Health Care Cost Institute found that daily deaths in the United States were over 10 percent higher in 2020 than they had been in previous years. The data showed dramatic variations by geography. Since the end of March, New York daily death figures were double those from previous years. While New York deaths appeared to be declining by April, other states were on the rise.

Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings from the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study

Jordan B. Strom, Kamil F. Faridi, Neel M. Butala, Yuansong Zhao, Hector Tamez, Linda R. Valsdottir, J. Matthew Brennan, Changyu Shen, Jeffrey J. Popma, Dhruv S. Kazi, and Robert W. Yeh

The study attempted to see whether passively collected data could substitute for adjudicated outcomes to reproduce the magnitude and direction of treatment effect observed in cardiovascular clinical trials. By linking together a variety of data sets, including clinical trials and medicare inpatient claims, the researchers concluded that the clinical trial and the claims data produced magnitudinally and directionally consistent results for the primary endpoints, though less so for the secondary endpoints.

Privacy-Preserving Record Linkage to Identify Fragmented Electronic Medical Records in the All of Us Research Program

Abel N. Kho, Jingzhi Yu, Molly Scannell Bryan, Charon Gladfelter, Howard S. Gordon, Shaun Grannis, Margaret Madden, Eneida Mendonca, Vesna Mitrovic, Raj Shah, Umberto Tachinardi, and Bradley Taylor

In conjunction with the All of Us Research Program, the authors looked at Electronic Health Records to understand how fragmented patient data was across a variety of health provider organizations, using a Privacy-Preserving Record Linkage tool in participating sites to generate a unique set of keyed encrypted hashes. Of the 5,831,238 individuals, 458,680 patients had data at more than one institution. Patients with some care fragmentation were almost 10 times as likely to have conflicting or inconsistent demographic data.

Showing 5-8 of 22 Studies